Cargando…
Intestinal current measurement and nasal potential difference to make a diagnosis of cases with inconclusive CFTR genetics and sweat test
BACKGROUND: Nasal potential difference (NPD) and intestinal current measurements (ICM) are cystic fibrosis transmembrane conductance regulator (CFTR) biomarkers recommended to make a diagnosis in individuals with inconclusive sweat test and CFTR genetics and a clinical suspicion for cystic fibrosis...
Autores principales: | Minso, Rebecca, Schulz, Angela, Dopfer, Christian, Alfeis, Nadine, van Barneveld, Andrea, Makartian-Gyulumyan, Lena, Hansen, Gesine, Junge, Sibylle, Müller, Carsten, Ringshausen, Felix C C, Sauer-Heilborn, Annette, Stanke, Frauke, Stolpe, Cornelia, Tamm, Stephanie, Welte, Tobias, Dittrich, Anna-Maria, Tümmler, Burkhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537139/ https://www.ncbi.nlm.nih.gov/pubmed/33020115 http://dx.doi.org/10.1136/bmjresp-2020-000736 |
Ejemplares similares
-
Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies
por: Bresnick, Kathryn, et al.
Publicado: (2021) -
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
por: Bessonova, Leona, et al.
Publicado: (2018) -
Adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: analysis of a national specialty pharmacy database
por: Mehta, Zumi, et al.
Publicado: (2021) -
Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design
por: Jain, Raksha, et al.
Publicado: (2022) -
Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials
por: Keogh, Ruth H, et al.
Publicado: (2022)